Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Plby Group Inc (PLBY) Price & Performance

Abbott LaboratoriesTrade
Plby Group IncTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Plby Group Inc — how do they compare? Abbott Laboratories trades at $110.73 (market cap $187.95B), while Plby Group Inc trades at $1.26 (market cap $162.94M). The key difference: Abbott Laboratories is far larger — about 1153.5× Plby Group Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.

ABTPLBY
Market Cap
$187.95B$162.94M
Sector
HealthConsumer Cyclical
52-Week High
$136.62$2.71
52-Week Low
$82.57$1.11
Enterprise Value
$214.96B$308.52M
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

Plby Group Inc

PLBY trades at $1.28, up 8.47% in the last session, with a bullish technical signal from moving averages. The company shows improving fundamentals, with Q2 2026 revenue growth and a return to operating profitability, while net income margin remains slim at 0.23%. Recent news highlights inclusion in the Russell 2000 index and a share repurchase program.

The outlook is cautiously optimistic, supported by analyst consensus and positive cash flow trends, but high debt levels and inconsistent earnings history pose risks. Investment opportunity lies in brand licensing growth, while execution and competitive pressures are key watchpoints.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Plby Group Inc

PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.

Read more on PLBY